Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Abcellera Biologics Inc stock
Learn how to easily invest in Abcellera Biologics Inc stock.
AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
How to buy shares in Abcellera Biologics Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ABCL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Abcellera Biologics Inc stock price (NASDAQ: ABCL)Use our graph to track the performance of ABCL stocks over time.
Abcellera Biologics Inc shares at a glance
|Latest market close||$10.64|
|52-week range||$5.42 - $22.63|
|50-day moving average||$8.26|
|200-day moving average||$11.64|
|Wall St. target price||$30.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.64|
Buy Abcellera Biologics Inc shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Abcellera Biologics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Abcellera Biologics Inc price performance over time
|1 week (2022-06-28)||3.70%|
|1 month (2022-06-01)||36.41%|
|3 months (2022-04-05)||5.77%|
|6 months (2022-01-05)||-13.21%|
|1 year (2021-07-02)||-48.05%|
|2 years (2020-07-01)||N/A|
|3 years (2019-07-01)||N/A|
|5 years (2017-07-01)||N/A|
Is Abcellera Biologics Inc stock undervalued or overvalued?
Valuing Abcellera Biologics Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcellera Biologics Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abcellera Biologics Inc's P/E ratio
Abcellera Biologics Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Abcellera Biologics Inc shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Abcellera Biologics Inc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Abcellera Biologics Inc's EBITDA
Abcellera Biologics Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $286.4 million.
The EBITDA is a measure of a Abcellera Biologics Inc's overall financial performance and is widely used to measure a its profitability.
To put Abcellera Biologics Inc's EBITDA into context you can compare it against that of similar companies.
Abcellera Biologics Inc financials
|Revenue TTM||$489 million|
|Operating margin TTM||55.47%|
|Gross profit TTM||$267.6 million|
|Return on assets TTM||12.46%|
|Return on equity TTM||18.92%|
|Market capitalisation||$3 billion|
TTM: trailing 12 months
Abcellera Biologics Inc share dividends
We're not expecting Abcellera Biologics Inc to pay a dividend over the next 12 months.
Abcellera Biologics Inc overview
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Abcellera Biologics Inc in the news
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
Insiders rewarded with a US$7.1m addition on top of their US$20m purchase as AbCellera Biologics Inc. (NASDAQ:ABCL) hits US$2.9b
AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?
Frequently asked questionsWhat percentage of Abcellera Biologics Inc is owned by insiders or institutions?
Currently 28.823% of Abcellera Biologics Inc shares are held by insiders and 40.319% by institutions. How many people work for Abcellera Biologics Inc?
Latest data suggests 400 work at Abcellera Biologics Inc. When does the fiscal year end for Abcellera Biologics Inc?
Abcellera Biologics Inc's fiscal year ends in December. Where is Abcellera Biologics Inc based?
Abcellera Biologics Inc's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 What is Abcellera Biologics Inc's ISIN number?
Abcellera Biologics Inc's international securities identification number is: CA00288U1066
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert